Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera

imedex has 1334 videos Subscribe Here

Description: Dr. Tiziano Barbui and Dr. Srdan Verstovsek debate “Position of JAK2 inhibitors as second line therapy in PV: Strictly for HU resistant/intolerant patients or do they have a broader application?” presented during the satellite symposium Great Debates and Clinical Considerations for the Utilization of JAK2 Inhibitors in the Treatment of Myeloproliferative Neoplasms at the 2015 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress held in Zagreb, Croatia, 24-26 April 2015. Within this educational activity discussion of pertinent clinical trials and review and analysis of clinical outcomes are utilized to evaluate whether JAK2 inhibitor therapy should only be used as a second-line therapy for PV patients who are resistant/intolerant to HU.

Earn accreditation for this activity at the following location:

© 2015 Imedex, LLC.
Shared By : imedex
Posted on : 06/08/15
Added : 4 years ago